|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The highest rate of discordant assignments occurred between the luminal A and luminal B subtypes and between the luminal B and ERBB2 subtypes.
|
16846532 |
2006 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The molecular subtypes were defined as: luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or PR+, HER2+), basal-like (ER-, PR-, HER2-), and Her-2/neu (ER-, PR-, and HER2+).
|
17950079 |
2007 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, luminal B and HER2 molecular phenotypes were both more frequent among DCIS (13.2% and 13.6%, respectively) as compared with invasive tumours (5.2% and 5.7%, respectively) (p < 0.0001).
|
18681955 |
2008 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression profiling studies have suggested that HER2-amplified breast cancers constitute a heterogeneous group that may be subdivided according to their ER status: HER2-amplified ER-positive breast carcinomas that fall into the luminal B cluster; and HER2-amplified ER-negative cancers which form a distinct molecular subgroup, known as the erbB2 or HER2 subgroup.
|
18810758 |
2008 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These included 15 of 21 BLC and 9 of 12 UTNC, but only 1 of 14 HER-2 positive cases and none of the 17 luminal A or 7 luminal B cases (P<0.01, BLC or UTNC vs. others).
|
18936692 |
2009 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of the 205 tumors, 113 (55%) were classified as Luminal A, 34 (17%) as Luminal B, 32 (15%) as TN, 8 (4%) as ERBB2, 10 (5%) as Luminal A-HER2 Hybrid, and 8 (4%) as Luminal B-HER2 Hybrid.
|
19801938 |
2010 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A cohort of 26,767 breast cancer patients were divided in four groups: luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or PR+ HER2+), HER2+ (ER-, PR-, HER2+), and triple-negative (ER-, PR-, HER2-).
|
20574671 |
2010 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
By using the intrinsic gene set defined by Hu et al. five molecular subtypes (Basal(mRNA), HER2+(mRNA), Luminal A(mRNA), Luminal B(mRNA) and Normal-like(mRNA)) can be defined.
|
19669409 |
2010 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Luminal B (ER(+) ; HER2(+) ) and luminal A (ER(+) ; HER(-) ) subtypes were identified in 12% and 2% of cases, respectively.
|
20955381 |
2010 |
|
Luminal B Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The mean of age at diagnosis was 51.5 years for luminal A; 49.6 for luminal B; 49.5 for basal-like; and 49.4 for HER2.
|
20705562 |
2010 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cancers were categorized as luminal A (ER-alpha+ and/or PR+ and HER2-); luminal B (ER-alpha+ and/or PR+ and HER2+); HER2 (ER-alpha- and PR- and HER2+); and basal-like (ER-alpha-, PR-, HER2- and EGFR or cytokeratin 5/6+).
|
19898422 |
2010 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two molecular subtype classifications based on conventional immunohistochemical and fluorescent in situ hybridization determinations were used: #1: Four groups segregated according to the combination of hormone receptor (HR) and HER2 status; #2: Intrinsic subtype classification (Triple Negative (TN), HER2, Luminal B and Luminal A).
|
20037779 |
2010 |
|
Luminal B Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In contrast htid expression is significantly lower in tumors of the Luminal B (20%) and HER-2 (18%) subtype over expressing the receptor and in the triple negative (40%) more aggressive malignancies.
|
20565727 |
2010 |
|
Luminal B Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The equation of RS = 17.489 + 2.071 (tubal formation) + 2.926 (mitosis) -2.408 (PR) -1.061 (HER2) + 7.051 (luminal A) + 29.172 (luminal B) predicts RS with an R² of 0.65.
|
20690804 |
2010 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The luminal A subtype accounted for 49.7% of all cases, the HER2-positive subtype for 27.9%, and only 10.4% and 12.0% represented the luminal B and basal-like subtypes, respectively.
|
21095069 |
2011 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Breast carcinomas (n=103) identified between 2001 and 2010 from patients seen at the Johns Hopkins Hospital were categorized into luminal A (n=18), luminal B (n=28), HER-2-positive (n=20) and triple-negative carcinomas (n=37) based on tumor characteristics.
|
21057458 |
2011 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression level of ERCC1 was the lowest in TNBC type (P = 0.031), ERCC1 negativity was more prominent in TNBC and luminal B groups than luminal A and HER-2 groups (P = 0.013).
|
21394302 |
2011 |
|
Luminal B Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In study group 2, the KRAS variant was significantly enriched in women with triple-negative breast cancer (19 [21%] of 90 cases) compared with 64 (13%) of 478 for luminal A, 13 (15%) of 87 for luminal B, and two (6%) of 35 for HER2-positive subgroups (p=0.044).
|
21435948 |
2011 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cases were classified as luminal A (ER+ and/or PR+, and HER2- and Ki67 low), luminal B (ER+ and/or PR+, and HER2+ or Ki67 high), HER2 driven (ER-, PR-, HER2+), basal-like (ER-, PR-, HER2-, CK5/6+ and/or CK14+ and/or EGFR+), or unclassifiable triple-negative (negative for all six markers).
|
22056953 |
2012 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the 298 tumors, the immunohistochemical panel classified 37 (12%) as luminal A, 198 (66%) as luminal B, 27 (9%) as HER2 enriched, and 36 (12%) as TNBC.
|
21901395 |
2012 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ER positive cohort was subsequently divided into Luminal A, Luminal B HER2 negative and Luminal B HER2 positive subtypes.
|
22489698 |
2012 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently it has been shown that immunohistochemistry (IHC) markers including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her2), can divide tumors to main subtypes: luminal A (ER+; PR+/-; HER-2-), luminal B (ER+;PR+/-; HER-2+), basal-like (ER-;PR-;HER2-) and Her2+ (ER-; PR-; HER-2+).
|
23098526 |
2012 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For 44 Taiwanese breast cancers with survival data, a better prognosis of luminal A than luminal B subtype in ER-postive breast cancers and a better prognosis of basal-like than HER2-enriched subtype in ER-negative breast cancers was observed.
|
23046482 |
2012 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, GSTP1 promoter hypermethylation might be implicated more importantly in the pathogenesis of luminal A, luminal B and HER2-enriched tumors than basal-like tumors.
|
22320227 |
2012 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
High expression of CCNE2, but not CCNE1, was characteristic of the luminal B and HER2 subtypes of breast cancer and was strongly predictive of shorter distant metastasis-free survival following endocrine therapy.
|
22564725 |
2012 |